Release date: 2024-08-08 15:50:25 Article From: Lucius Laos Recommended: 154
Exkivity is a broad-spectrum inhibitor that broadly inhibits multiple mutant kinases on lung cells, blocking the proliferation and migration of tumor cells. For patients with NSCLC with EGFR exon 20 insertion mutations, Exkivity can specifically target this mutation site to inhibit tumor growth and metastasis.
Exkivity is highly effective in the treatment of lung cancer patients with specific gene mutations, which can not only effectively control the development of tumors, but also significantly improve the quality of life and prognosis of patients. Exkivity offers new treatment options and hope for lung cancer patients.
The excellent metabolic stability and tissue permeability of Exkivity allow the drug ingredient to be better absorbed and utilized by patients, thereby improving the therapeutic effect. At the same time, it can cross the blood-brain barrier and have an effect on brain metastases, which is especially important for patients with advanced lung cancer.
Exkivity has shown good therapeutic results in the treatment of specific types of cancer, providing patients with new hope and possibilities. Specific efficacy may vary from person to person, and patients should follow their doctor's guidance when using it.
The use of Exkivity is accompanied by a range of potential adverse effects, of which anemia is one of the more common.
Exkivity inhibits the growth of tumor cells through its specific mechanism of action, but this process may also affect the normal hematopoietic function of the bone marrow, especially the production of red blood cells. The bone marrow is the main site of red blood cell production, and when Exkivity interferes with this process, it can lead to a low number of red blood cells, which can lead to anemia.
Patients should inform their doctor immediately if they develop the above symptoms of anemia while taking Exkivity. Your doctor will evaluate your condition and may take the following steps to relieve symptoms:
If the anemia is directly caused by Exkivity, your doctor may consider adjusting the dose or temporarily stopping the drug to lessen the suppression of the bone marrow's hematopoiesis.
For anemia caused by insufficient raw materials for hematopoiesis, your doctor may recommend supplementation with nutrients needed for your blood, such as iron, folic acid, and vitamin B12.
【Warm tips】When patients buy generic drugs, they should choose formal channels to ensure the quality and safety of the drugs. Avoid purchasing counterfeit products from informal sources.
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:2012024-09-07
On November 14, 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medi···【more】
Recommended:1582025-13-01
Recent advancements have reaffirmed the significance of liquid biopsy in the management of advanced ···【more】
Recommended:1562025-06-01
FDA Approves First Generic Version of Victoza (liraglutide injection)The U.S. Food and Drug Administ···【more】
Recommended:1712024-30-12
The new indication involves the treatment of adult patients with locally advanced, unresectable non-···【more】
Recommended:1612024-24-12
he U.S. Food and Drug Administration (FDA) has approved Crenessity (crinecerfont) for use in combina···【more】
Recommended:1462024-17-12
In the phase Ib/II multicenter pivotal FELIX study, the autologous 41BB-ζ anti-CD19 chimeric antigen···【more】
Recommended:1052024-13-12
On 25 July 2024, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHM···【more】
Recommended:2482024-26-08
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: